![]() |
市場調査レポート
商品コード
950711
COVID-19ワクチンと治療薬の世界市場:270種類以上のワクチンと治療薬の開発が進行中、2020年~2024年COVID-19 Vaccines & COVID-19 Drugs Market 2020-2024: More Than 270 COVID-19 Drugs & Vaccines Currently Under Development |
COVID-19ワクチンと治療薬の世界市場:270種類以上のワクチンと治療薬の開発が進行中、2020年~2024年 |
出版日: 2020年07月24日
発行: Homeland Security Research Corporation (HSRC)
ページ情報: 英文 250 Pages; 130 Tables & Figures
納期: 即日から翌営業日
|
新型コロナウイルス感染症(COVID-19)のパンデミックが続くなか、2020年6月26日の時点で270を超える治療薬とワクチンの開発が進められています(このうちの約85%が前臨床段階)。
医薬品研究のアプローチとしては、体内で繁殖するウイルスの能力に直接影響を与える抗ウイルス薬、免疫系が過剰反応し心臓や腎臓などに害を及ぼすような場面で免疫系を落ち着かせる薬、ウイルスを攻撃する抗体の3つがあります。
ワクチン開発には、通常8年から12年の歳月が必要であり、専門家の多くは、18ヶ月でワクチンを開発するのは非常に厳しいスケジュールであると指摘しています。楽観的なシナリオとして、2021年7月までに数千万人分のワクチンが準備できるとの見方もありますが、その一方で2025年まで集団予防接種はできないという見方もあります。
当レポートは、世界のCOVID-19ワクチンと治療薬の市場を調査したもので、成長促進要因と阻害要因、ビジネスチャンス、SWOT分析、競合分析、事業環境などの情報を提供しています。
The Coronavirus pandemic has led to an acute deficiencies of COVID-19 therapeutic drugs, COVID-19 vaccines, other COVID-19 pharma products, and vaccines manufacturing lines. Once medical regulating bodies certify the vaccines and therapeutic drugs to be safe and effective, legislators, regulation agencies and the global healthcare community will be faced with ration and allocation dilemmas when distributing these lifesaving medicines.
The global pharma industry and medical research bodies are investing in and concentrating resources on discovering and developing COVID-19 drugs and vaccines. There are more than 270 (approximately 85% in the pre-clinical phase) drugs and vaccines under development as of June 26, 2020.
There are more than 140 distinct therapeutic drugs being researched around the world. The majority of current drugs that are being trialed against the virus. WHO has introduced the Solidarity trial aimed at assessing the most promising treatments
There are three main COVID-19 drug investigation approaches:
Vaccine creators are rushing to develop COVID-19 vaccines and have enhanced ten candidates entered into clinical trials.
Vaccine development is typically a long game. For example, the FDA approved a first vaccine against Ebola virus last year, 43 years after the Ebola virus was revealed. Vaccine developers have made little headway with HIV or pulmonary syncytial virus, in spite of massive investments. It takes 8-12 years on average, to develop a vaccine. With the COVID-19 crisis looming, everyone is hoping that this time will be different.
Most experts argue that 18 months for a first vaccine is an extremely hard-hitting schedule, some believe that tens of millions of COVID-19 vaccines doses might be prepared for distribution by July 2021. Nobody knows, if and when a safe and effective vaccine will save the day.
The team which composed this report brings 43 years of hands on record in the development and commercialization of healthcare products including: antibody antigen detection, E-health, decontamination and biosecurity, PACS, teleradiology, PPE, computerized tomography, medical devices and more. Our team members bring long term relations with the U.S. FDA and CDC as well as the EU CE and other national medical regulatory agencies.
To adhere to our high standards of research, as nobody can forecast the future of the pandemic, we include in the report two scenarios: